Sichuan Kelun-Biotech Biopharmaceutical Co (HKSE:06990) Debt-to-EBITDA : N/A (As of Dec. 2023)

View and export this data going back to 2023. Start your Free Trial

What is Sichuan Kelun-Biotech Biopharmaceutical Co Debt-to-EBITDA?

Debt-to-EBITDA measures a company's ability to pay off its debt.

Sichuan Kelun-Biotech Biopharmaceutical Co's Short-Term Debt & Capital Lease Obligation for the quarter that ended in Dec. 2023 was HK$59.5 Mil. Sichuan Kelun-Biotech Biopharmaceutical Co's Long-Term Debt & Capital Lease Obligation for the quarter that ended in Dec. 2023 was HK$6.0 Mil. Sichuan Kelun-Biotech Biopharmaceutical Co's annualized EBITDA for the quarter that ended in Dec. 2023 was HK$0.0 Mil.

A high Debt-to-EBITDA ratio generally means that a company may spend more time to paying off its debt. According to Joel Tillinghast's BIG MONEY THINKS SMALL: Biases, Blind Spots, and Smarter Investing, a ratio of Debt-to-EBITDA exceeding four is usually considered scary unless tangible assets cover the debt.

The historical rank and industry rank for Sichuan Kelun-Biotech Biopharmaceutical Co's Debt-to-EBITDA or its related term are showing as below:

HKSE:06990' s Debt-to-EBITDA Range Over the Past 10 Years
Min: -8.58 Med: -3.17 Max: -0.19
Current: -0.26

During the past 3 years, the highest Debt-to-EBITDA Ratio of Sichuan Kelun-Biotech Biopharmaceutical Co was -0.19. The lowest was -8.58. And the median was -3.17.

HKSE:06990's Debt-to-EBITDA is ranked worse than
100% of 276 companies
in the Biotechnology industry
Industry Median: 1.37 vs HKSE:06990: -0.26

Sichuan Kelun-Biotech Biopharmaceutical Co Debt-to-EBITDA Historical Data

The historical data trend for Sichuan Kelun-Biotech Biopharmaceutical Co's Debt-to-EBITDA can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Sichuan Kelun-Biotech Biopharmaceutical Co Debt-to-EBITDA Chart

Sichuan Kelun-Biotech Biopharmaceutical Co Annual Data

Trend

Dec21

Dec22

Dec23

Debt-to-EBITDA

-3.17

-8.58

-0.19

Sichuan Kelun-Biotech Biopharmaceutical Co Quarterly Data
	Sep21	Dec21	Jun22	Sep22	Dec22	Jun23	Dec23
Debt-to-EBITDA	Get a 7-Day Free Trial			N/A	77.38	-3.19	N/A	N/A

Competitive Comparison of Sichuan Kelun-Biotech Biopharmaceutical Co's Debt-to-EBITDA

For the Biotechnology subindustry, Sichuan Kelun-Biotech Biopharmaceutical Co's Debt-to-EBITDA, along with its competitors' market caps and Debt-to-EBITDA data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Sichuan Kelun-Biotech Biopharmaceutical Co's Debt-to-EBITDA Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Sichuan Kelun-Biotech Biopharmaceutical Co's Debt-to-EBITDA distribution charts can be found below:

* The bar in red indicates where Sichuan Kelun-Biotech Biopharmaceutical Co's Debt-to-EBITDA falls into.

Sichuan Kelun-Biotech Biopharmaceutical Co Debt-to-EBITDA Calculation

Debt-to-EBITDA measures a company's ability to pay off its debt.

Sichuan Kelun-Biotech Biopharmaceutical Co's Debt-to-EBITDA for the fiscal year that ended in Dec. 2023 is calculated as

Debt-to-EBITDA	=	Total Debt			/	EBITDA
	=	(Short-Term Debt & Capital Lease Obligation	+	Long-Term Debt & Capital Lease Obligation)	/	EBITDA
	=	(59.508	+	6.03)	/	-337.22
	=	-0.19

Sichuan Kelun-Biotech Biopharmaceutical Co's annualized Debt-to-EBITDA for the quarter that ended in Dec. 2023 is calculated as

Debt-to-EBITDA	=	Total Debt			/	EBITDA
	=	(Short-Term Debt & Capital Lease Obligation	+	Long-Term Debt & Capital Lease Obligation)	/	EBITDA
	=	(59.508	+	6.03)	/	0
	=	N/A

In the calculation of annual Debt-to-EBITDA, the EBITDA of the last fiscal year is used. In calculating the annualized quarterly data, the EBITDA data used here is four times the quarterly (Dec. 2023) EBITDA data.

Sichuan Kelun-Biotech Biopharmaceutical Co (HKSE:06990) Debt-to-EBITDA Explanation

In the calculation of Debt-to-EBITDA, we use the total of Short-Term Debt & Capital Lease Obligation and Long-Term Debt & Capital Lease Obligation divided by EBITDA. In some calculations, Total Liabilities is used to for calculation.

Be Aware

A high Debt-to-EBITDA ratio generally means that a company may spend more time to paying off its debt.

According to Joel Tillinghast's BIG MONEY THINKS SMALL: Biases, Blind Spots, and Smarter Investing, a ratio of Debt-to-EBITDA exceeding four is usually considered scary unless tangible assets cover the debt.

Sichuan Kelun-Biotech Biopharmaceutical Co Debt-to-EBITDA Related Terms

Thank you for viewing the detailed overview of Sichuan Kelun-Biotech Biopharmaceutical Co's Debt-to-EBITDA provided by GuruFocus.com. Please click on the following links to see related term pages.

Sichuan Kelun-Biotech Biopharmaceutical Co (HKSE:06990) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Sichuan Kelun-Biotech Biopharmaceutical Co Ltd (HKSE:06990) » Definitions » Debt-to-EBITDA

Comparable Companies

Traded in Other Exchanges

N/A

Address

No. 666 Xinhua Avenue, Chengdu Cross-Strait Science and Technology Industry Development Park, Wenjiang, Sichuan, Chengdu, CHN

Website

http://www.kelun-biotech.com

Sichuan Kelun-Biotech Biopharmaceutical Co Ltd is an innovative biopharmaceutical company committed to the R&D, manufacturing and commercialization of novel drugs to address medical needs in China and globally. It is one of the first movers in the development of antibody-drug conjugates (ADCs), with over a decade of accumulated experience in ADC development. The company takes a systematic, indication-oriented approach to target the world's prevalent or hard-to-treat cancers, and other diseases and conditions affecting a large and underserved population.

Sichuan Kelun-Biotech Biopharmaceutical Co (HKSE:06990) Headlines

No Headlines